ロード中...

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients

Background: Reliable markers of disease outcomes in multiple sclerosis (MS) would help to predict the response to treatment in patients treated with high efficacy drugs. No evidence of disease activity (NEDA) has become a treatment goal whereas the modified Rio score (MRS) predicts future suboptimal...

詳細記述

保存先:
書誌詳細
出版年:J Clin Med
主要な著者: Jamroz-Wiśniewska, Anna, Zajdel, Radosław, Słowik, Agnieszka, Marona, Monika, Wnuk, Marcin, Adamczyk-Sowa, Monika, Adamczyk, Bożena, Lasek-Bal, Anetta, Puz, Przemysław, Stęposz, Arkadiusz, Krzystanek, Ewa, Patalong-Ogiewa, Maja, Pokryszko-Dragan, Anna, Budrewicz, Sławomir, Koziarska, Dorota, Karbicka, Anna, Wawrzyniak, Sławomir, Fryze, Waldemar, Furtak-Niczyporuk, Marzena, Rejdak, Konrad
フォーマット: Artigo
言語:Inglês
出版事項: MDPI 2021
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8122749/
https://ncbi.nlm.nih.gov/pubmed/33922368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10091830
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!